FDA approves first pill to treat all forms of hepatitis C
Federal health officials have approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
The Food and Drug Administration approved the combination pill from Gilead Sciences Inc. for patients with and without liver damage.
The agency has approved a number of hepatitis C drugs in the last three years, but all were targeted to specific strains of the virus or patients with various stages of liver disease.
Epclusa, the new pill from Gilead, combines the Foster City, Calif., company’s first hepatitis drug, Sovaldi, with a new drug that attacks the virus using a different mechanism.
Gilead’s hepatitis pills have raked in billions of dollars by replacing an older approach that involved a grueling pill-and-injection cocktail.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
